BV
BVNRY.US Bavarian Nordic A/S ADR
- Market cap
- USD 2.61B
- P/E
- 11.6x
- P/B
- 1.34x
- ROE
- 11.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BVNRY.US undervalued?
Graham numberBVNRY.US trades 17.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bavarian Nordic A/S ADR fundamental analysis
No fundamental analysis for Bavarian Nordic A/S ADR yet.
Bavarian Nordic A/S ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bavarian Nordic A/S ADR
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN …
Full company profileBavarian Nordic A/S ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bavarian Nordic A/S ADR annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.01B | 1.37B | 501M | 662M | 1.85B | 1.90B | 3.15B | 7.06B | 5.72B | 5.93B | 6.28B |
| Gross Profit | 709M | 1.08B | 246M | 308M | 657M | 570M | 1.70B | 4.53B | 2.82B | 2.81B | 3.46B |
| Operating Income | 67.3M | 308M | -320M | -316M | 450M | -263M | -3.85M | 1.50B | 940M | 885M | 1.50B |
| EBITDA | 88.6M | 459M | -300M | -269M | 674M | 85.9M | 84.3M | 2.05B | 1.67B | 1.60B | 2.21B |
| Net Income | 30.6M | 181M | -362M | -347M | 278M | -465M | -347M | 1.48B | 988M | 1.32B | 1.52B |
| EPS | 0.27 | 1.50 | -2.96 | -2.83 | 1.71 | -2.46 | -1.64 | 6.41 | 4.20 | 5.65 | 6.68 |
| Balance Sheet | |||||||||||
| Total Assets | 2.82B | 3.15B | 3.06B | 7.05B | 8.76B | 12.1B | 12.4B | 14.4B | 14.4B | 15.0B | 14.7B |
| Total Liabilities | 806M | 646M | 880M | 5.18B | 3.86B | 4.71B | 5.24B | 4.01B | 3.00B | 2.08B | 1.51B |
| Shareholders' Equity | 2.02B | 2.51B | 2.18B | 1.87B | 4.89B | 7.37B | 7.15B | 10.3B | 11.4B | 12.9B | 13.2B |
| Cash & Short-term Investments | 1.91B | 2.59B | 2.32B | 472M | 1.67B | 3.72B | 2.85B | 1.87B | 2.18B | 3.33B | 2.36B |
| Total Debt | 31.9M | 402M | 646M | 1.83B | 470M | 1.13B | 1.76B | 145M | 128M | 131M | 131M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 268M | 216M | -289M | -276M | 572M | -359M | 220M | 1.12B | 1.95B | 2.62B | -809M |
| Capital Expenditure | 91.5M | 78.7M | 212M | 2.67B | 707M | 1.06B | 1.38B | 977M | 1.69B | 197M | 109M |
| Free Cash Flow | 176M | 137M | -500M | -2.95B | -135M | -1.42B | -1.16B | 142M | 262M | 2.42B | -918M |
| Ratios | |||||||||||
| ROE | 1.5% | 7.2% | -16.6% | -18.6% | 5.7% | -6.3% | -4.9% | 14.3% | 8.7% | 10.3% | 11.5% |
| ROA | 1.1% | 5.8% | -11.8% | -4.9% | 3.2% | -3.8% | -2.8% | 10.3% | 6.9% | 8.8% | 10.3% |
| Net Profit Margin | 3.0% | 13.2% | -72.3% | -52.3% | 15.0% | -24.5% | -11.0% | 20.9% | 17.3% | 22.3% | 24.2% |
| Debt to Equity | 0.02x | 0.16x | 0.30x | 0.98x | 0.10x | 0.15x | 0.25x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bavarian Nordic A/S ADR dividends
Bavarian Nordic A/S ADR has not paid dividends in the last 9 fiscal years.
Last stock split: 1277:1000 on Mar 30, 2020.
Who owns Bavarian Nordic A/S ADR
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 224M
- Free float 248M
Bavarian Nordic A/S ADR company profile
- Company name
- Bavarian Nordic A/S ADR
- Ticker
- BVNRY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,692
- Fiscal year end
- December
- Address
- Philip Heymans Alle 3, Hellerup, Denmark, 2900
- Phone
- 45 33 26 83 83
- Website
- bavarian-nordic.com
About Bavarian Nordic A/S ADR
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Bavarian Nordic A/S ADR management
5- Mr. Henrik Juuel M.Sc.CFO & Executive VP · born 1965
- Ms. Tarja StenvallPresident & CEO
- Mr. Russell Thirsk M.Sc.Executive VP & COO · born 1968
- Ms. Nicole SeroffVice President Corporate Communications
- Mr. Jean-Christophe May M.B.A., Pharm.D.Executive VP & Chief Commercial Officer · born 1967